Abstract 784P
Background
The incidence of HPV integration is increased during the disease progression from precancerous lesions to carcinoma, and HPV integration is reputed as a key effect to escape eliminations from the host cells. Although HPV integration is identified in HPV-related carcinoma, the mechanisms underlying HPV carcinogenesis remain unclear.
Methods
Here, 6768 HPV integration sites from cervical carcinoma (CESC) and 470 from head & neck carcinoma (HNSC), high-through chromosome conformation capture (Hi-C), ChIP-seq, ChIP-PCR and RNA-seq were analyzed to identify the HPV integration characteristics in HPV-host interactions. Manual HPV-integration cells, an HPV integration mouse model (K14-HPV, FVB/N), and CRISPR-Cas9 knock-out cells were performed to demonstrate the chromatin remolding between universal stripe factors (USFs) and super-enhancers.
Results
In CESC and HNSC, USF motifs were enriched in HPV integration sites and integrated HPV-host interaction regions. In addition, HPV integration sites and integrated HPV-host interaction regions marked increased chromatin accessibility (ATAC-seq) and super-enhancer elements (H3K27ac, H3K4me1, and H3K4me3), with USF motifs enrichment in these regions. By dividing the tumor samples according to HPV status, USF genes were found to be upregulated in CESC and HNSC, which could be validated by tumor samples, manual HPV-integration cells, and the K14-HPV integration mouse model. Furthermore, three-dimensional chromatin analyses reveal the chromatin interactions between USF genes and super enhancers in tumor cells. The expression patterns of USF genes and chromatin interactions between USF genes and the super-enhancer were reversed via super-enhancer CRISPR-Cas9 knock-out, thus reversing malignant phenotypes of tumor cells in vitro and in vivo.
Conclusions
Overall, we identify that HPV integration remodels chromatin interactions between USFs and super enhancers to promote malignant phenotypes in HPV-related carcinoma, which provides insight into the three-dimensional mechanism in HPV-related carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. CAO.
Funding
National Key R&D Program of China (21YFC2701201) and the National Natural Science Foundation of China (82072895, 82141106, and 82203453).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11